Quanta Inc (fka QNTA)

[JediMozart]

they have stated goals publicly

listen to latest the cc
At this Time stamp
13:40 QNTA Main GOALS & PLANS discussed

They’ve spelled out numerous things that were in the works Also I’ve shared the link before with detailed notes of where things were mentioned
I’ll paste my notes once again at the bottom of this note … with the link to watch the cc and the passcode at the very bottom of this page below the list of times of things discussed (for example at 13:40 minute mark QNTA Main GOALS & PLANS)

Should you want to reach out with specific questions/ concerns / ideas etc
Here is the contact information
[e-mail]

Below is a quick reference guide I compiled to easily pin points where topics were discussed on the CC many said they didn’t have time to watch in entirety so I took a morning and made notes … (it’s quite possible I missed something but it’s pretty comprehensive)
hopefully you find it helpful
HOWEVER if you have specific questions pertaining to the cc and or otherwise send an email mark it attention Grant Mikaelian and ask directly… the cc covers a lot and will give you a good starting point to hear the plans etc

key topics that were discussed
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 some Paxlovid users had symptoms relapse, versus with escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient LUNG X-ray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine ** lots of very good informative easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]***<<
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 explains COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 *** FDA strategy summarized
“Actively working to completely FDA process”
*** Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 “Shared CEO” position defined - active negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company(s) to NASDAQ
- roles of co-ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination of research to where qnta is now and moving forward toward to a continued path to achieving goals
***
GLTA
***
Cc link and code link below;

Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)

Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r